Evidence map›Paper›PMID 37143658›Full record

ArticleFrontiers in immunology2023

Haemagglutination inhibition and virus microneutralisation serology assays: use of harmonised protocols and biological standards in seasonal influenza serology testing and their impact on inter-laboratory variation and assay correlation: A FLUCOP collaborative study.

Joanna Waldock, Edmond J Remarque, Lingyi Zheng, Sammy Ho, Katja Hoschler, Britta Neumann, Hanna Sediri-Schön, Claudia M Trombetta, Emanuele Montomoli, Serena Marchi and 13 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Observational
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 10 institutions in 8 countries.

Joanna WaldockInfluenza Resource Centre, Vaccines, Science Research & Innovation, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom.
Edmond J RemarqueDepartment of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands.
Lingyi ZhengDepartment of Research and Development, Sanofi, Marcy L'Etoile, France.
Sammy HoRespiratory Viruses Unit, UK Health Secruity Agency, Colindale, United Kingdom.
Katja HoschlerRespiratory Viruses Unit, UK Health Secruity Agency, Colindale, United Kingdom.
Britta NeumannSection for Viral Vaccines, Virology Division, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.
Hanna Sediri-SchönSection for Viral Vaccines, Virology Division, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.
Claudia M TrombettaDepartment of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
Emanuele MontomoliDepartment of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
Serena MarchiDepartment of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
Giulia LapiniVismederi srl, Siena, Italy.
Fan ZhouInfluenza Centre, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
Sarah L LarteyInfluenza Centre, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
Rebecca J CoxInfluenza Centre, Department of Clinical Sciences, University of Bergen, Bergen, Norway.
Marzia FacchiniWorld Health Organisation (WHO) National Influenza Centre, Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy.
Maria Rita CastrucciWorld Health Organisation (WHO) National Influenza Centre, Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy.
Damien FrielGSK, Wavre, Belgium.
Thierry OllingerGSK, Wavre, Belgium.
Catherine CailletDepartment of Research and Development, Sanofi, Marcy L'Etoile, France.
Nedzad MusicSeqirus, Cambridge, MA, United States.
Giuseppe PalladinoSeqirus, Cambridge, MA, United States.
Othmar G EngelhardtInfluenza Resource Centre, Vaccines, Science Research & Innovation, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom.
FLUCOP consortium
University of Bergen · NOUniversity of Siena · ITGlaxoSmithKline (Belgium) · BEIstituto Superiore di Sanità · ITPaul Ehrlich Institut · DESanofi (France) · FRSeqirus (United States) · USUK Health Security AgencyBiomedical Primate Research Centre · NLVisMederi Research · IT

Funding

World Health Organization 001
6 · The paper itself

Abstract

Introduction: The haemagglutination inhibition assay (HAI) and the virus microneutralisation assay (MN) are long-established methods for quantifying antibodies against influenza viruses. Despite their widespread use, both assays require standardisation to improve inter-laboratory agreement in testing. The FLUCOP consortium aims to develop a toolbox of standardised serology assays for seasonal influenza. Building upon previous collaborative studies to harmonise the HAI, in this study the FLUCOP consortium carried out a head-to-head comparison of harmonised HAI and MN protocols to better understand the relationship between HAI and MN titres, and the impact of assay harmonisation and standardisation on inter-laboratory variability and agreement between these methods. Methods: In this paper, we present two large international collaborative studies testing harmonised HAI and MN protocols across 10 participating laboratories. In the first, we expanded on previously published work, carrying out HAI testing using egg and cell isolated and propagated wild-type (WT) viruses in addition to high-growth reassortants typically used influenza vaccines strains using HAI. In the second we tested two MN protocols: an overnight ELISA-based format and a 3-5 day format, using reassortant viruses and a WT H3N2 cell isolated virus. As serum panels tested in both studies included many overlapping samples, we were able to look at the correlation of HAI and MN titres across different methods and for different influenza subtypes. Results: We showed that the overnight ELISA and 3-5 day MN formats are not comparable, with titre ratios varying across the dynamic range of the assay. However, the ELISA MN and HAI are comparable, and a conversion factor could possibly be calculated. In both studies, the impact of normalising using a study standard was investigated, and we showed that for almost every strain and assay format tested, normalisation significantly reduced inter-laboratory variation, supporting the continued development of antibody standards for seasonal influenza viruses. Normalisation had no impact on the correlation between overnight ELISA and 3-5 day MN formats.

Indexed as

Influenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesAntibodies, ViralHemagglutinationHumansInfluenza A Virus, H3N2 SubtypeSeasonsAntibodies, ViralInfluenza Vaccineshaemagglutination inhibition assay (HAI)influenza virusesserologystandardisationvirus microneutralisation assay (MN)

Identifiers

PMID37143658
PMCPMC10151801
OpenAlexW4366290801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.